Invivoscribe said May 9 that the deal is aimed at accelerating the molecular diagnostics and precision medicine businesses of both companies. Hitachi’s expertise in measurement and analysis systems technologies is expected to complement Invivoscribe’s technology, assay and bioinformatics development, clinical testing and international regulatory expertise.
“Hitachi manufactures and distributes in-vitro diagnostic instruments that we currently use to standardize testing for the international community; we are looking forward to further deepening our partnership so we can advance precision medicine worldwide,” Invivoscribe CEO Jeffrey Miller, PhD, said in a news release.
